An interventional study of YouControl-A-Fib mHealth Application in Atrial Fibrillation, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 484th largest by enrollment of the 679 interventional ones that give a count, is one of 54 that started in 2024, is one of 405 with no phase, and was the 894th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 40+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 54 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
75 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 75 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to establish the feasibility of performing a clinical trial using a mHealth application named YouControl-AFib designed to improve the cardiovascular health of persons with atrial fibrillation. The study will obtain feedback on the app design to inform future versions and will collect preliminary data to support proof-of-concept and potential effect sizes for future trial design.
Primary Objective
Secondary Objectives
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: YouControl-A-Fib mHealth Application
Participants will use the app for 3 months, includes 1 month phone call with Health Coach
Average Number of Participants Recruited Per Month
Time frame: up to 6 months
Maximum Number of Participants Recruited in a Single Month
Time frame: up to 6 months
Mobile App Rating Scale Score
Mobile App Rating Scale contains several subscales that will each be scored on a scale of 1-5; B-functionality, C-aesthetics, and D-information. Higher scores indicate high levels of functionality, aesthetics, and information quality. The overall mean score for all sub-scales is reported here.
Time frame: 3 months
Change in 6-minute Walk Distance (Compared to Baseline for Each Participant) After Using the mHealth App for 3 Months
Time frame: baseline, 3 months
Weekly Step Count After Using the mHealth App for Three Months
Time frame: week 1, week 12
Intentional Activity Time (in One Week) After Using the mHealth App for Three Months
Time frame: week 1, week 12
General Quality of Life Questionnaire: SF-12 Physical Component Summary Score
SF-12 measures the impact of health on the participant's life and is scored from 0-100 where higher scores indicates higher health related quality of life.
Time frame: baseline, 3 months
General Quality of Life Questionnaire: SF-12 Mental Component Summary Score
SF-12 measures the impact of health on the participant's life and is scored from 0-100 where higher scores indicates higher health related quality of life.
Time frame: baseline, 3 months
Patient Health Questionnaire (PHQ-9) Score
PHQ-9 is a 9-item questionnaire scored on a 4 point likert scale from 0-3 for a total possible range of scores from 0-27. Higher scores indicate increased depression.
Time frame: baseline, 3 months
Change in Atrial Fibrillation Effect on Quality of Life Questionnaire (AFEQT) Score
AFEQT is a 20-item survey scored on a 7 point likert scale from 1-7 (total possible range of scores is converted to be from 0-100) where higher scores indicate higher effect that atrial fibrillation has on the participant's quality of life.
Time frame: baseline, 3 months
Atrial Fibrillation Symptom Severity (AFSS) Score
AFSS is a 7-item survey scored on a likert scale from 0-5 for a total possible range of scores from 0-35 where higher scores indicate greater symptom severity.
Time frame: baseline, 3 months
Percent Correct on the Atrial Fibrillation Knowledge Assessment Tool (AFKAT)
AFKAT is a 21-item true / false assessment that measures knowledge about atrial fibrillation. Correct answers are scored with a 1 for a total possible range of scores from 0-21. Higher scores indicate increased knowledge of atrial fibrillation. Reported here is the percent correct.
Time frame: baseline, 3 months
Life's Essential 8 Score After Using the mHealth App for Three Months
Life's Essential 8 score (LE8) is a composite score between 0-100 that assesses a participant's adherence to 8 lifestyle recommendations with improve cardiovascular health: diet, physical activity, smoking habits, body mass index, cholesterol, blood glucose, and sleep duration. Higher scores are indicative of higher adherence to healthy lifestyle.
Time frame: baseline, 3 months
Irregular Heart Rate Notifications (in One Week) After Using the mHealth App for Three Months
Time frame: baseline, 3 months
Change in ECG-age After Using the mHealth App for Three Months
Participants will obtain single-lead ECGs at baseline and after three months. The time-voltage data are run through an ECG-AI model for estimating ECG-age. ECG-age is a novel metric developed by investigators at Wake Forest. See reference section for relevant publication describing a similar model. Summary results will be reported as ECG-age in years.
Time frame: baseline, 3 months
Recruitment occurred over 6 months, 10/17/2024 - 4/15/2025
| Milestone | People Using YouControl-A-Fib App |
|---|---|
| Started | 51 |
| Analysis population | 51 |
| Pre and post 6 minute walk data | 48 |
| Completed | 48 |
| Not completed | 3 |
| Withdrew: Lost to follow-up | 3 |
| participants per month | People Using YouControl-A-Fib App |
|---|---|
| Average Number of Participants Recruited Per Month | 8.5 ± 3.6 |
| Participants | People Using YouControl-A-Fib App |
|---|---|
| Maximum Number of Participants Recruited in a Single Month | 15 |
Mobile App Rating Scale contains several subscales that will each be scored on a scale of 1-5; B-functionality, C-aesthetics, and D-information. Higher scores indicate high levels of functionality, aesthetics, and information quality. The overall mean score for all sub-scales is reported here.
| score on a scale | People Using YouControl-A-Fib App |
|---|---|
| Mobile App Rating Scale Score | 4.1 ± 0.6 |
| meters | People Using YouControl-A-Fib App |
|---|---|
| Change in 6-minute Walk Distance (Compared to Baseline for Each Participant) After Using the mHealth App for 3 Months | 29.1 ± 56.3 |
| steps per week | People Using YouControl-A-Fib App |
|---|---|
| First Full Week | 38772 ± 20613 |
| 12th Full Week | 40823 ± 26093 |
| minutes | People Using YouControl-A-Fib App |
|---|---|
| First Full Week | 219 ± 260 |
| 12th Full Week | 210 ± 275 |
SF-12 measures the impact of health on the participant's life and is scored from 0-100 where higher scores indicates higher health related quality of life.
| score on a scale | People Using YouControl-A-Fib App |
|---|---|
| baseline | 40.4 ± 4.3 |
| 3 months | 41.8 ± 5.3 |
SF-12 measures the impact of health on the participant's life and is scored from 0-100 where higher scores indicates higher health related quality of life.
| score on a scale | People Using YouControl-A-Fib App |
|---|---|
| baseline | 48.0 ± 5.5 |
| 3 months | 48.0 ± 4.9 |
PHQ-9 is a 9-item questionnaire scored on a 4 point likert scale from 0-3 for a total possible range of scores from 0-27. Higher scores indicate increased depression.
| score on a scale | People Using YouControl-A-Fib App |
|---|---|
| baseline | 4.7 ± 3.3 |
| 3 months | 3.9 ± 3.5 |
AFEQT is a 20-item survey scored on a 7 point likert scale from 1-7 (total possible range of scores is converted to be from 0-100) where higher scores indicate higher effect that atrial fibrillation has on the participant's quality of life.
| score on a scale | People Using YouControl-A-Fib App |
|---|---|
| baseline | 78.8 ± 15.6 |
| 3 months | 83.4 ± 14.6 |
AFSS is a 7-item survey scored on a likert scale from 0-5 for a total possible range of scores from 0-35 where higher scores indicate greater symptom severity.
| score on a scale | People Using YouControl-A-Fib App |
|---|---|
| baseline | 6.9 ± 5.5 |
| 3 months | 6.1 ± 5.5 |
AFKAT is a 21-item true / false assessment that measures knowledge about atrial fibrillation. Correct answers are scored with a 1 for a total possible range of scores from 0-21. Higher scores indicate increased knowledge of atrial fibrillation. Reported here is the percent correct.
| percent correct | People Using YouControl-A-Fib App |
|---|---|
| baseline | 91 ± 6 |
| 3 months | 92 ± 14 |
Life's Essential 8 score (LE8) is a composite score between 0-100 that assesses a participant's adherence to 8 lifestyle recommendations with improve cardiovascular health: diet, physical activity, smoking habits, body mass index, cholesterol, blood glucose, and sleep duration. Higher scores are indicative of higher adherence to healthy lifestyle.
| score on a scale | People Using YouControl-A-Fib App |
|---|---|
| baseline | 52.7 ± 9.1 |
No measurements were reported for this outcome.
Participants will obtain single-lead ECGs at baseline and after three months. The time-voltage data are run through an ECG-AI model for estimating ECG-age. ECG-age is a novel metric developed by investigators at Wake Forest. See reference section for relevant publication describing a similar model. Summary results will be reported as ECG-age in years.
Results for this outcome have not been posted.
Collected over up to 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| People Using YouControl-A-Fib App | 0/51 (0%) | 0/51 (0%) | 0/51 (0%) |
| Age, Continuous(years) | People Using YouControl-A-Fib App |
|---|---|
| Mean | 63.1 ± 9.5 |
| Sex: Female, Male(Participants) | People Using YouControl-A-Fib App |
|---|---|
| Female | 26 |
| Male | 25 |
| Race (NIH/OMB)(Participants) | People Using YouControl-A-Fib App |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 51 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | People Using YouControl-A-Fib App |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 51 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | People Using YouControl-A-Fib App |
|---|---|
| United States | 51 |
| Geographic Location(Participants) | People Using YouControl-A-Fib App |
|---|---|
| Urban | 21 |
| Non-Urban | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. Every attempt will be made to publish results in peer-reviewed journals.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting the PI.
Ran from Oct 2024 to primary completion in Jul 2025, 9 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 9 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →